grant
Project 2 - BWH
Organization BETH ISRAEL DEACONESS MEDICAL CENTERLocation BOSTON, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2025AmericanAntibodiesApicalAutomobile DrivingBindingBlood SerumBody TissuesCD3CD3 AntigensCD3 ComplexCD3 moleculeCTLA-8CTLA-8 GeneCTLA8CTLA8 GeneCell BodyCell CommunicationCell Communication and SignalingCell InteractionCell SignalingCell-to-Cell InteractionCellsClinical Treatment MoabCytotoxic T-Lymphocyte-Associated Antigen 8Cytotoxic T-Lymphocyte-Associated Antigen 8 GeneCytotoxic T-Lymphocyte-Associated Serine Esterase 8Cytotoxic T-Lymphocyte-Associated Serine Esterase 8 GeneDataDevelopmentDiseaseDisease OutcomeDisorderDrug KineticsDrugsEncapsulatedExperimental DesignsFamilyFluorescence AgentsFluorescent AgentsFluorescent DyesFreezingGlycoproteinsHigh Endothelial VenuleHomingHumanIL-17IL-17 GeneIL-17AIL-17A GeneIL-23IL17IL17 ProteinIL17 geneIL17AIL17A GeneImmuneImmune RegulatorsImmune TargetingImmunesImmunomodulatorsImmunotherapeutic agentInflammationInflammatoryInterleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8)Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8) GeneInterleukin 17 PrecursorInterleukin 17 Precursor GeneInterleukin-17Intracellular Communication and SignalingKidneyKidney Urinary SystemKineticsKnowledgeLigandsLupus Erythematosus DisseminatusLupus GlomerulonephritisLupus NephritisLymph Node Reticuloendothelial SystemLymph node properLymphatic cellLymphatic nodesLymphocyteLymphocyticLymphoid CellLymphotoxinLymphotoxin ALymphotoxin-alphaLymphotoxin-αMaintenanceMediatingMedicationMember 1 TNF SuperfamilyMembraneMiceMice MammalsModern ManMolecularMolecular InteractionMonoclonal AntibodiesMurineMusOKT3 antigenPathogenesisPathway interactionsPatientsPeripheralPharmaceutical PreparationsPharmacokineticsPlayPropertyProteomicsProtocolProtocols documentationReceptor ProteinReceptor SignalingRoleSLESafetySeriesSerumSignal PathwaySignal TransductionSignal Transduction SystemsSignalingStromal CellsSurfaceSystemic Lupus ErythematosusSystemic Lupus ErythematousSystemic Lupus ErythmatosusT-CellsT-LymphocyteT3 AntigensT3 ComplexT3 moleculeTNF-bTNF-betaTNF-βTNFSF1TNFβTeff cellTestingTherapeuticTimeTissuesTreatment EfficacyTumor Necrosis Factor-BetaTumor Necrosis Factor-βValidationVeinsbiological signal transductiondevelopmentaldisseminated lupus erythematosusdosagedrivingdrug/agenteffector T cellefficacy testingfluorescent dye/probeimmune drugsimmune modulatorsimmune-based therapeuticsimmunologic therapeuticsimmunomodulatory moleculesimmunoregulatorimmunoregulatory moleculesimmunotherapeuticsimmunotherapy agentimprovedinnovateinnovationinnovativeinsightinterleukin-23intervention efficacyintravenous administrationkidney biopsylymph celllymph glandlymph nodeslymphnodesmAbsmembrane structuremonoclonal Absnanonano particlenano polymernano-sized particlenanoparticlenanoparticle therapynanopolymernanosized particlenanotherapeuticnovelpathwaypodoplaninprecision medicineprecision-based medicinepreventpreventingreceptorrecruitrenalrenal biopsysite targeted deliverysmall moleculesocial rolespatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicssystemic lupus erythematosistargeted deliverytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttechnology platformtechnology systemtherapeutic efficacytherapeutic nanoparticlestherapeutically effectivetherapy efficacythymus derived lymphocytetooltraffickingvalidationsvenulezeta potential
Description preview
Systemic lupus erythematosus (SLE) afflicts 1 to 2 million Americans, and an estimated 50-60% of these patients
develop lupus nephritis (LN) during the first 10 years of disease. The management of LN is still challenging,
despite the development of numerous new classes of immune therapeutics. Intrarenal inflammation is a defining
feature for LN,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click